PubMed
Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
Richie JP Jr, Nichenametla S, Neidig W, et al. Eur J Nutr. 2015
Compare
Glutathione vs Retatrutide
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
Glutathione
38 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Mood
135
Recovery
1
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Digestive upset
3
Self-reported dose per injection
Median bucket: 5+ mg · Most common: 5+ mg
Reports span 0.2 to ≥ 5 mg (open-ended top bucket)
0.2–0.4 mg
1
0.4–0.6 mg
1
1–2 mg
10
2–3 mg
3
5+ mg
120
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 96% said they felt similar to their last entry, 4% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 66 days · Based on 26 repeat reporters
Retatrutide
125 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 99% · Mixed 1% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
222
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
3
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 1–2 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
5
0.1–0.2 mg
3
0.2–0.4 mg
6
0.4–0.6 mg
10
0.6–1 mg
5
1–2 mg
80
2–3 mg
35
3–5 mg
17
5+ mg
61
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 100% said they felt similar to their last entry, 0% more positive, and 0% more negative.
Overall, repeat reporters leaned similar or mixed compared to their previous entry.
Median gap between entries: 51 days · Based on 45 repeat reporters
Sources (10)
Published sources linked on the Glutathione and Retatrutide wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Intravenous glutathione for skin lightening: Inadequate safety data
Davids LM, van Wyk JC, Khumalo NP. S Afr Med J. 2016
- Wiki study page →Source
PubMed
Dietary glutathione supplementation enhances antioxidant activity and protects against lipopolysaccharide-induced acute hepatopancreatic injury and cell apoptosis in Chinese mitten crab, Eriocheir sinensis
Liu JD, Liu WB, Zhang CY, et al. Fish & shellfish immunology. 2020
- Wiki study page →Source
PubMed
Glutathione and Selenium Supplementation Attenuates Liver Injury in Diethylnitrosamine-Induced Hepatocarcinogenic Mice by Enhancing Glutathione-Related Antioxidant Capacities
Hsiao YF, Huang SC, Cheng SB, et al. International journal of molecular sciences. 2024
- Wiki study page →Source
PubMed
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
Rosenstock J, Frias J, Jastreboff AM, et al. Lancet. 2023
- Wiki study page →Source
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frias JP, et al. N Engl J Med. 2023
- Wiki study page →Source
ClinicalTrials.gov
Retatrutide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
ClinicalTrials.gov
Retatrutide studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. The New England journal of medicine. 2023
- Wiki study page →Source
PubMed
Retatrutide-A Game Changer in Obesity Pharmacotherapy
Katsi V, Koutsopoulos G, Fragoulis C, et al. Biomolecules. 2025